search
Back to results

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Primary Purpose

Dermatitis, Atopic

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BMS-986166
Branebrutinib
Placebo
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dermatitis, Atopic focused on measuring Atopic Dermatitis, BMS-986166, BMS-986195, Branebrutinib

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Chronic atopic dermatitis (AD) diagnosed according to the Eichenfield modification of Hanifin's and Rajka's (E-HR) criteria at Screening
  • Disease duration of at least 24 months since diagnosis by any criteria
  • Documented history of inadequate control of AD by a stable regimen (≥ 4 weeks) of topical corticosteroids, calcineurin inhibitors or biologics, within 6 months of randomization, or inappropriateness of therapy due to side effects or safety risks leading to prior discontinuation
  • Application of fixed doses of an additive-free, basic bland emollient twice-daily for ≥ 7 days before baseline visit and for the duration of the study

Exclusion Criteria:

  • Any major illness/condition or evidence of an unstable clinical condition or local active infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study or interfere with the interpretation of study results
  • Clinically relevant cardiovascular conditions or pulmonary conditions
  • High likelihood - based on participant history, and investigator judgement - of requiring rescue therapy in < 4 weeks prior to randomization
  • Evidence of acute flare between the Screening and Baseline/ Randomization
  • Skin lesion(s) and/or pruritus due to conditions other than AD that would interfere with the study specified assessments

Other protocol-defined inclusion/exclusion criteria apply

Sites / Locations

  • Local Institution - 0091
  • Local Institution - 0112
  • Local Institution - 0061
  • Local Institution - 0110
  • Local Institution - 0006
  • Local Institution
  • Local Institution - 0008
  • Local Institution - 0081
  • Local Institution - 0083
  • Dermatology and Skin Cancer Specialists, LLC
  • Local Institution - 0051
  • Local Institution
  • Local Institution - 0078
  • Local Institution - 0094
  • The University of Texas Health Science Center at Houston
  • Local Institution
  • Local Institution - 0003
  • Premier Dermatology
  • Holdsworth House Medical Practice
  • Westmead Hospital-Dermatology
  • Sinclair Dermatology
  • Local Institution
  • Local Institution
  • York Dermatology Clinic and Research Centre
  • SIMa Recherche
  • Charité Universitaetsmedizin Berlin - Campus Mitte
  • Local Institution
  • Local Institution - 0034
  • Universitätsklinikum Bonn-Studienzentrum Dermatologie
  • SRH Wald-Klinikum Gera-Zentrum für klinische Studien
  • Local Institution
  • Universitatsklinikum Schleswig-Holstein
  • Local Institution
  • KliFOs - Klinische Forschung Osnabrück
  • Private Practice - Dr. Ralph von Kiedrowski
  • Royalderm Agnieszka Nawrocka
  • NZOZ Centrum Medyczne KERmed
  • ETYKA Osrodek Badan Klinicznych
  • Local Institution - 0130
  • Hospital General Universitario de Alicante-Dermatology
  • Hospital Universitario de Gran Canaria Doctor Negrín-Dermatología
  • Hospital Universitario La Paz-UCICEC/DERMA

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Arm Label

Placebo

Treatment BMS-986166 Dose 1

Treatment BMS-986166 Dose 2

Treatment BMS-986166 Dose 3

Treatment Branebrutinib

Arm Description

Outcomes

Primary Outcome Measures

Mean Percentage Change From Baseline in EASI Score at Week 16
The Eczema Area and Severity Index (EASI) is a validated, composite scoring system assessed by the investigator based on the extent of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD and the intensity of each of 4 key signs of AD (erythema, induration/papulation, excoriation, and lichenification) and is based on a 4-point scale of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe). For each of the 4 body regions, the mean intensity of inflamed lesions for each of the 4 signs is recorded. Xerosis, scaling, urticaria, or post-inflammatory pigmentation changes are not included. The total EASI score ranges from 0 to 72. The lower the score the better.

Secondary Outcome Measures

Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16
The vIGA-AD is a static 5-point assessment intended to assess the global severities of key acute clinical signs of AD, including erythema, induration/papulation, and oozing/crusting (lichenification excluded). The rating of cleared (0), almost cleared (1), mild (2), moderate (3), and severe (4) will be assessed.
Percentage of Participants Exhibiting a ≥ 50% (EASI-50) Reduction From Baseline in EASI Score at Week 16
The Eczema Area and Severity Index (EASI) is a validated, composite scoring system assessed by the investigator based on the extent of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD and the intensity of each of 4 key signs of AD (erythema, induration/papulation, excoriation, and lichenification) and is based on a 4-point scale of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe). For each of the 4 body regions, the mean intensity of inflamed lesions for each of the 4 signs is recorded. Xerosis, scaling, urticaria, or post-inflammatory pigmentation changes are not included. The total EASI score ranges from 0 to 72. The lower the score the better.
Percentage of Participants Exhibiting a ≥ 4-point Improvement From Baseline in Pruritus NRS at Week 16
Participants will complete a daily diary recording the intensity of their pruritus they experienced during the preceding 24 hours. The intensity of pruritus will be assessed using a validated 11-point NRS, ranging from 0 ("no itching") to 10 ("the worst itching imaginable"). The lower the score the better.
Mean Percentage Change From Baseline in Pruritus NRS Score at Week 16
Participants will complete a daily diary recording the intensity of their pruritus and the average quality of sleep they experienced during the preceding 24 hours. The intensity of pruritus will be assessed using a validated 11-point NRS, ranging from 0 ("no itching") to 10 ("the worst itching imaginable"). The quality of sleep will be assessed using a validated 11-point NRS ranging from 0 ("the best possible sleep") to 10 ("the worst possible sleep). The lower the score the better.
Mean Change From Baseline in Percentage of Affected BSA at Week 16
A widely used method of measuring Body Surface Area (BSA) involvement by AD, is the rule of nines in which for each section of the body (the possible highest score for each region is: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], genitals [1%]) and will be reported as a percentage of all major body sections combined.
Number of Participants With Mild Moderate or Severe AEs
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities. Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event, and both AEs and SAEs can be assessed as severe.
Number of Participants With Mild Moderate or Severe SAEs
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death is life threatening Requires inpatient hospitalization or causes prolongation of existing hospitalization Results in persistent or significant disability Is a congenital anomaly/birth defect. Is an important medical event
Number of Participants With Clinically Relevant ECG Abnormalities
12 Lead Electrocardiogram (ECG). The participant will remain supine for 5 to 10 minutes prior to the ECG and must have lab work done after the tracing so that the ECG results remain as accurate as possible.
Number of Participants With Clinically Relevant OCT Abnormalities
Optical coherence tomography (OCT) is a non-invasive imaging test. It uses light waves to take cross-section pictures of your retina. Diagnosis is made by an ophthalmologist.
Number of Participants With Clinically Relevant PFT Abnormalities
Pulmonary function tests (PFT) include: forced expiratory volume (FEV1), percent predicted FEV1, forced vital capacity (FVC), percent predicted FVC, and Diffusion capacity of carbon monoxide (DLCO).
Number of Participants With Clinically Meaningful Changes in Vital Signs
The following vital signs will be assessed: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate and body temperature.
Number of Participants With Clinically Relevant Changes in LFTs
Liver Function Tests (LFTs) will include the following measurements: ALT OR AST > 3 X ULN ALT OR AST > 5 X ULN ALT OR AST > 8 X ULN TOTAL BILIRUBIN > 2 X ULN ALT OR AST > 3 X ULN AND (TOTAL BILIRUBIN > 2 X ULN OR INR >1.5) AST = aspartate aminotransferase ALT = alanine aminotransferase ULN = Upper limit number INR = International Normalized Ratio

Full Information

First Posted
July 29, 2021
Last Updated
September 25, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT05014438
Brief Title
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Official Title
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
August 17, 2021 (Actual)
Primary Completion Date
August 22, 2022 (Actual)
Study Completion Date
August 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dermatitis, Atopic
Keywords
Atopic Dermatitis, BMS-986166, BMS-986195, Branebrutinib

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Treatment BMS-986166 Dose 1
Arm Type
Experimental
Arm Title
Treatment BMS-986166 Dose 2
Arm Type
Experimental
Arm Title
Treatment BMS-986166 Dose 3
Arm Type
Experimental
Arm Title
Treatment Branebrutinib
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BMS-986166
Intervention Description
Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
Branebrutinib
Other Intervention Name(s)
BMS-986195
Intervention Description
Specified dose on specified days
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Specified dose on specified days
Primary Outcome Measure Information:
Title
Mean Percentage Change From Baseline in EASI Score at Week 16
Description
The Eczema Area and Severity Index (EASI) is a validated, composite scoring system assessed by the investigator based on the extent of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD and the intensity of each of 4 key signs of AD (erythema, induration/papulation, excoriation, and lichenification) and is based on a 4-point scale of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe). For each of the 4 body regions, the mean intensity of inflamed lesions for each of the 4 signs is recorded. Xerosis, scaling, urticaria, or post-inflammatory pigmentation changes are not included. The total EASI score ranges from 0 to 72. The lower the score the better.
Time Frame
From baseline and 16 weeks
Secondary Outcome Measure Information:
Title
Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16
Description
The vIGA-AD is a static 5-point assessment intended to assess the global severities of key acute clinical signs of AD, including erythema, induration/papulation, and oozing/crusting (lichenification excluded). The rating of cleared (0), almost cleared (1), mild (2), moderate (3), and severe (4) will be assessed.
Time Frame
From baseline and 16 weeks
Title
Percentage of Participants Exhibiting a ≥ 50% (EASI-50) Reduction From Baseline in EASI Score at Week 16
Description
The Eczema Area and Severity Index (EASI) is a validated, composite scoring system assessed by the investigator based on the extent of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD and the intensity of each of 4 key signs of AD (erythema, induration/papulation, excoriation, and lichenification) and is based on a 4-point scale of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe). For each of the 4 body regions, the mean intensity of inflamed lesions for each of the 4 signs is recorded. Xerosis, scaling, urticaria, or post-inflammatory pigmentation changes are not included. The total EASI score ranges from 0 to 72. The lower the score the better.
Time Frame
From baseline and 16 weeks
Title
Percentage of Participants Exhibiting a ≥ 4-point Improvement From Baseline in Pruritus NRS at Week 16
Description
Participants will complete a daily diary recording the intensity of their pruritus they experienced during the preceding 24 hours. The intensity of pruritus will be assessed using a validated 11-point NRS, ranging from 0 ("no itching") to 10 ("the worst itching imaginable"). The lower the score the better.
Time Frame
From baseline and 16 weeks
Title
Mean Percentage Change From Baseline in Pruritus NRS Score at Week 16
Description
Participants will complete a daily diary recording the intensity of their pruritus and the average quality of sleep they experienced during the preceding 24 hours. The intensity of pruritus will be assessed using a validated 11-point NRS, ranging from 0 ("no itching") to 10 ("the worst itching imaginable"). The quality of sleep will be assessed using a validated 11-point NRS ranging from 0 ("the best possible sleep") to 10 ("the worst possible sleep). The lower the score the better.
Time Frame
From baseline and 16 weeks
Title
Mean Change From Baseline in Percentage of Affected BSA at Week 16
Description
A widely used method of measuring Body Surface Area (BSA) involvement by AD, is the rule of nines in which for each section of the body (the possible highest score for each region is: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], genitals [1%]) and will be reported as a percentage of all major body sections combined.
Time Frame
From baseline and 16 weeks
Title
Number of Participants With Mild Moderate or Severe AEs
Description
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities. Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event, and both AEs and SAEs can be assessed as severe.
Time Frame
From initial treatment to 30 days post discontinuation, approximately 29 weeks
Title
Number of Participants With Mild Moderate or Severe SAEs
Description
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death is life threatening Requires inpatient hospitalization or causes prolongation of existing hospitalization Results in persistent or significant disability Is a congenital anomaly/birth defect. Is an important medical event
Time Frame
From initial treatment to 30 days post discontinuation, approximately 29 weeks
Title
Number of Participants With Clinically Relevant ECG Abnormalities
Description
12 Lead Electrocardiogram (ECG). The participant will remain supine for 5 to 10 minutes prior to the ECG and must have lab work done after the tracing so that the ECG results remain as accurate as possible.
Time Frame
Week 24 after initial treatment
Title
Number of Participants With Clinically Relevant OCT Abnormalities
Description
Optical coherence tomography (OCT) is a non-invasive imaging test. It uses light waves to take cross-section pictures of your retina. Diagnosis is made by an ophthalmologist.
Time Frame
Week 24 after initial treatment
Title
Number of Participants With Clinically Relevant PFT Abnormalities
Description
Pulmonary function tests (PFT) include: forced expiratory volume (FEV1), percent predicted FEV1, forced vital capacity (FVC), percent predicted FVC, and Diffusion capacity of carbon monoxide (DLCO).
Time Frame
Week 24 after initial treatment
Title
Number of Participants With Clinically Meaningful Changes in Vital Signs
Description
The following vital signs will be assessed: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate and body temperature.
Time Frame
Week 24 after initial treatment
Title
Number of Participants With Clinically Relevant Changes in LFTs
Description
Liver Function Tests (LFTs) will include the following measurements: ALT OR AST > 3 X ULN ALT OR AST > 5 X ULN ALT OR AST > 8 X ULN TOTAL BILIRUBIN > 2 X ULN ALT OR AST > 3 X ULN AND (TOTAL BILIRUBIN > 2 X ULN OR INR >1.5) AST = aspartate aminotransferase ALT = alanine aminotransferase ULN = Upper limit number INR = International Normalized Ratio
Time Frame
Week 24 after initial treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic atopic dermatitis (AD) diagnosed according to the Eichenfield modification of Hanifin's and Rajka's (E-HR) criteria at Screening Disease duration of at least 24 months since diagnosis by any criteria Documented history of inadequate control of AD by a stable regimen (≥ 4 weeks) of topical corticosteroids, calcineurin inhibitors or biologics, within 6 months of randomization, or inappropriateness of therapy due to side effects or safety risks leading to prior discontinuation Application of fixed doses of an additive-free, basic bland emollient twice-daily for ≥ 7 days before baseline visit and for the duration of the study Exclusion Criteria: Any major illness/condition or evidence of an unstable clinical condition or local active infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study or interfere with the interpretation of study results Clinically relevant cardiovascular conditions or pulmonary conditions High likelihood - based on participant history, and investigator judgement - of requiring rescue therapy in < 4 weeks prior to randomization Evidence of acute flare between the Screening and Baseline/ Randomization Skin lesion(s) and/or pruritus due to conditions other than AD that would interfere with the study specified assessments Other protocol-defined inclusion/exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0091
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Facility Name
Local Institution - 0112
City
Brandon
State/Province
Florida
ZIP/Postal Code
33511
Country
United States
Facility Name
Local Institution - 0061
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Local Institution - 0110
City
Margate
State/Province
Florida
ZIP/Postal Code
33063
Country
United States
Facility Name
Local Institution - 0006
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Local Institution
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Local Institution - 0008
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60077
Country
United States
Facility Name
Local Institution - 0081
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Facility Name
Local Institution - 0083
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Facility Name
Dermatology and Skin Cancer Specialists, LLC
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Local Institution - 0051
City
Saint Joseph
State/Province
Missouri
ZIP/Postal Code
64506
Country
United States
Facility Name
Local Institution
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Local Institution - 0078
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19103
Country
United States
Facility Name
Local Institution - 0094
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
The University of Texas Health Science Center at Houston
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Local Institution
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
Local Institution - 0003
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26505
Country
United States
Facility Name
Premier Dermatology
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Facility Name
Holdsworth House Medical Practice
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Westmead Hospital-Dermatology
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Sinclair Dermatology
City
East Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Facility Name
Local Institution
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Local Institution
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 1X2
Country
Canada
Facility Name
York Dermatology Clinic and Research Centre
City
Richmond Hill
State/Province
Ontario
ZIP/Postal Code
L4C 9M7
Country
Canada
Facility Name
SIMa Recherche
City
Verdun
State/Province
Quebec
ZIP/Postal Code
H4G 3E7
Country
Canada
Facility Name
Charité Universitaetsmedizin Berlin - Campus Mitte
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Local Institution
City
Berlin
ZIP/Postal Code
12459
Country
Germany
Facility Name
Local Institution - 0034
City
Bochum
ZIP/Postal Code
44793
Country
Germany
Facility Name
Universitätsklinikum Bonn-Studienzentrum Dermatologie
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
SRH Wald-Klinikum Gera-Zentrum für klinische Studien
City
Gera
ZIP/Postal Code
07548
Country
Germany
Facility Name
Local Institution
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Universitatsklinikum Schleswig-Holstein
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Local Institution
City
Munich
ZIP/Postal Code
80337
Country
Germany
Facility Name
KliFOs - Klinische Forschung Osnabrück
City
Osnabrück
ZIP/Postal Code
49074
Country
Germany
Facility Name
Private Practice - Dr. Ralph von Kiedrowski
City
Selters
ZIP/Postal Code
56242
Country
Germany
Facility Name
Royalderm Agnieszka Nawrocka
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-962
Country
Poland
Facility Name
NZOZ Centrum Medyczne KERmed
City
Bydgoszcz
ZIP/Postal Code
85-231
Country
Poland
Facility Name
ETYKA Osrodek Badan Klinicznych
City
Olsztyn
ZIP/Postal Code
10-117
Country
Poland
Facility Name
Local Institution - 0130
City
Cordoba
State/Province
Andalucía
ZIP/Postal Code
14004
Country
Spain
Facility Name
Hospital General Universitario de Alicante-Dermatology
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
Hospital Universitario de Gran Canaria Doctor Negrín-Dermatología
City
Las
ZIP/Postal Code
35010
Country
Spain
Facility Name
Hospital Universitario La Paz-UCICEC/DERMA
City
Madrid
ZIP/Postal Code
28046
Country
Spain

12. IPD Sharing Statement

Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

We'll reach out to this number within 24 hrs